Elan Plc (ELN)

Market is closed

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

News

First
<< Previous
41 - 50
Next >>

BP plc (ADR) (BP), Oracle Corporation (ORCL): Value Investor Seth Klarman's Shakeups

Seth Klarman's Baupost Group, led by the famed value investor and author of Margin of Safety, recently revealed its public equity portfolio in its quarterly filing with the SEC.

Keep Reading →

May 22nd, 2013 - Hedge Funds

GlaxoSmithKline plc (ADR) (GSK), Sanofi SA (ADR) (SNY), Theravance Inc (THRX): This Week in Biotech

With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.

Keep Reading →

May 20th, 2013 - News

Hedge Fund News: Steven Cohen, Omega Advisors, Goldman Sachs Group, Inc. (GS)

Editor's Note: Related Tickers: Goldman Sachs Group, Inc. (NYSE:GS), Citigroup Inc. (NYSE:C), J.C. Penney Company, Inc. (NYSE:JCP), Herbalife Ltd.

Keep Reading →

May 17th, 2013 - Hedge Funds

Theravance Inc (THRX), GlaxoSmithKline plc (ADR) (GSK), Elan Corporation, plc (ADR) (ELN): Who Benefits From This Market Moving Biotechnology Partnership?

Back towards the end of April 2013, Theravance Inc (NASDAQ:THRX) surprised everyone when it announced plans to split into two separate companies.

Keep Reading →

May 14th, 2013 - News

Theravance Inc (THRX), Elan Corporation, plc (ADR) (ELN), GlaxoSmithKline plc (ADR) (GSK): Biotech Companies Breaking Up

Following in the footsteps of Abbott Laboratories (NYSE:ABT) spinning out its drug division into AbbVie Inc (NYSE:ABBV), and Pfizer spinning out its animal health division into animal health products...

Keep Reading →

April 26th, 2013 - News

Why Elan Corporation, plc (ADR) (ELN) Shouldn’t Take Royalty Pharma’s Sweetened Bid

Shunning a February $11 per share takeover bid from U.S. based pharmaceutical investment firm Royalty Pharma, Irish based Elan got a sweetened offer of up to $12 a share.

Keep Reading →

April 18th, 2013 - News

Biogen Idec Inc. (BIIB): What Goes up Must Come Down

Biogen Idec Inc. (NASDAQ:BIIB) is one of those rare companies in the healthcare sector whose stock has relentlessly outperformed the broader market continuously for as long as one can remember.

Keep Reading →

April 17th, 2013 - News

Hedge Fund News: Ray Dalio, David Einhorn, Groupon Inc (GPRN)

Editor's Note: Related tickers: UBS AG (USA) (NYSE:UBS), Morgan Stanley (NYSE:MS), Goldman Sachs Group, Inc. (NYSE:GS), Groupon Inc (NASDAQ:GRPN), J.C. Penney Company, Inc. (NYSE:JCP), Herbalife Ltd.

Keep Reading →

April 16th, 2013 - Hedge Funds

Biogen Idec Inc. (BIIB), Sanofi SA (ADR) (SNY), Elan Corporation, plc (ADR) (ELN): The Greatest Thing Since Sliced Bread Has Arrived for MS Patients

Last November, I examined five experimental drugs that appeared as if they had all of the tools necessary to become life-changing blockbusters from a financial and quality of life perspective.

Keep Reading →

March 28th, 2013 - News